In our cohort of lymphoma patients, CD66b+CD33dimHLA-DR− cells within PBMCs were mostly composed of CD11b+CD16+ LDNs (54.80 ± 2.97%, mean ± SD percentage), at significantly higher levels than the CD11b+CD16− (30.74 ± 2.30%) and CD11b−CD16− (13.19 ± 1.54%) subpopulations, (p < 0.0001). The gene discussed is CEACAM8; the disease is lymphoma.